SEC Form 4 · accession 0000899243-18-019319

Translate Bio, Inc. · TBIO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Jul 2, 2018

Accepted (ET)

Jul 3, 2018 · 6:37 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001693415

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Jul 2, 2018	C	3,832,010	—	A	3,922,010	I	By Atlas Venture Fund VIII, L.P.

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Series A Preferred Stock^F2,F1	—	Jul 2, 2018	C	12,925,244	D	—	—	Common Stock	2,326,567	I
Series B Preferred Stock^F2,F1	—	Jul 2, 2018	C	5,838,230	D	—	—	Common Stock	1,050,891	I
Series C Preferred Stock^F2,F1	—	Jul 2, 2018	C	2,525,253	D	—	—	Common Stock	454,550	I

F1The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.
F2These shares are held directly by Atlas Venture Fund VIII, L.P. ("Atlas Venture Fund VIII"). The sole general partner of Atlas Venture Fund VIII is Atlas Venture Associates VIII, L.P. ("AVA VIII LP"). Atlas Venture Associates VIII, Inc. ("AVA VIII INC") is the sole general partner of AVA VIII LP. Dr. Formela is a director of AVA VIII INC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund VIII, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed to be an admission that Dr. Formela is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.